Pages that link to "Q80374328"

The following pages link to Wnt signaling and the regulation of bone mass (Q80374328):

Displaying 40 items.

• Rapid-throughput skeletal phenotyping of 100 knockout mice identifies 9 new genes that determine bone strength (Q21563368) (← links)
• Disorders of Bone Remodeling (Q28295303) (← links)
• N-cadherin interacts with axin and LRP5 to negatively regulate Wnt/beta-catenin signaling, osteoblast function, and bone formation (Q28586879) (← links)
• Targeted disruption of the Wnt regulator Kremen induces limb defects and high bone density (Q28975610) (← links)
• Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women (Q33786865) (← links)
• Serotonergic Mechanisms Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance (Q33926234) (← links)
• miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. (Q34055717) (← links)
• Wnt pathway genes in osteoporosis and osteoarthritis: differential expression and genetic association study (Q34976255) (← links)
• Crosstalk between Wnt/β-catenin and estrogen receptor signaling synergistically promotes osteogenic differentiation of mesenchymal progenitor cells (Q35067794) (← links)
• Genetic analysis of high bone mass cases from the BARCOS cohort of Spanish postmenopausal women (Q35149544) (← links)
• Impaired bone formation in Pdia3 deficient mice (Q35432350) (← links)
• Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis (Q35694436) (← links)
• A DNA binding mutation in estrogen receptor-α leads to suppression of Wnt signaling via β-catenin destabilization in osteoblasts (Q35952286) (← links)
• Weight loss in obese older adults increases serum sclerostin and impairs hip geometry but both are prevented by exercise training (Q35992294) (← links)
• Advanced bone formation in mice with a dominant-negative mutation in the thyroid hormone receptor β gene due to activation of Wnt/β-catenin protein signaling. (Q36006828) (← links)
• Administration of an activin receptor IIB ligand trap protects male juvenile rhesus macaques from simian immunodeficiency virus-associated bone loss (Q36263420) (← links)
• Characterization of skeletal alterations in a model of prematurely aging mice (Q36670205) (← links)
• Role of Thyroid Hormones in Skeletal Development and Bone Maintenance (Q36773018) (← links)
• A novel semisynthetic molecule icaritin stimulates osteogenic differentiation and inhibits adipogenesis of mesenchymal stem cells. (Q36800940) (← links)
• Matrix-dependent adhesion mediates network responses to physiological stimulation of the osteocyte cell process (Q37031872) (← links)
• The Interplay between the bone and the immune system (Q37052226) (← links)
• Etanercept Promotes Bone Formation via Suppression of Dickkopf-1 Expression in Rats with Collagen-Induced Arthritis. (Q37140765) (← links)
• Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate (Q37196006) (← links)
• Secreted frizzled related protein 1 is a target to improve fracture healing (Q37374315) (← links)
• Acceleration of bone regeneration by activating Wnt/β-catenin signalling pathway via lithium released from lithium chloride/calcium phosphate cement in osteoporosis (Q37719513) (← links)
• Role of endocrine and paracrine factors in the adaptation of bone to mechanical loading (Q37850710) (← links)
• The regulation of valvular and vascular sclerosis by osteogenic morphogens (Q37919693) (← links)
• Osteoimmunology and bone homeostasis: relevance to spondyloarthritis (Q38109578) (← links)
• Semaphorin 3A: A new player in bone remodeling (Q38192834) (← links)
• From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD. (Q38367220) (← links)
• NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma (Q38921006) (← links)
• Evaluation of the bioactivity of recombinant human lactoferrins toward murine osteoblast-like cells for bone tissue engineering (Q39220278) (← links)
• Associations between the levels of sclerostin, phosphate, and fibroblast growth factor-23 and treatment with vitamin D in hemodialysis patients with low intact PTH level (Q44250442) (← links)
• Elevated levels of serum sclerostin are linked to adverse cardiovascular outcomes in peritoneal dialysis patients. (Q52709133) (← links)
• Bone Turnover Status: Classification Model and Clinical Implications. (Q55002406) (← links)
• The holy grail of high bone mass (Q84289299) (← links)
• Association of dietary and serum vitamin E with bone mineral density in middle-aged and elderly Chinese adults: a cross-sectional study (Q86568218) (← links)
• Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls (Q87238504) (← links)
• Cyclooxygenase 2 augments osteoblastic but suppresses chondrocytic differentiation of CD90+ skeletal stem cells in fracture sites (Q92488411) (← links)
• Molecular mechanosensors in osteocytes (Q96576112) (← links)